Giuseppe Saglio

Active 1976–2025

165
Papers
43,748
Citations
100
h-index
163
i10-index

Citations

Citations per year for Giuseppe Saglio1977: 1 citations1979: 21 citations1980: 1 citations1982: 1 citations1983: 2 citations1984: 5 citations1985: 3 citations1986: 1 citations1987: 3 citations1988: 5 citations1989: 7 citations1990: 9 citations1991: 11 citations1992: 10 citations1993: 17 citations1994: 16 citations1995: 17 citations1996: 25 citations1997: 29 citations1998: 51 citations1999: 86 citations2000: 70 citations2001: 75 citations2002: 110 citations2003: 165 citations2004: 141 citations2005: 175 citations2006: 192 citations2007: 304 citations2008: 291 citations2009: 372 citations2010: 378 citations2011: 376 citations2012: 346 citations2013: 340 citations2014: 319 citations2015: 331 citations2016: 333 citations2017: 260 citations2018: 239 citations2019: 877 citations2020: 979 citations2021: 866 citations2022: 625 citations2023: 391 citations2024: 748 citations2025: 237 citations2026: 2 citations1978: no citations, so this year is not shown1981: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,370 citing papers, 23.9% of this breakdownItaly: 937 citing papers, 9.5% of this breakdownGermany: 805 citing papers, 8.1% of this breakdownUnited Kingdom: 719 citing papers, 7.3% of this breakdownFrance: 586 citing papers, 5.9% of this breakdownChina: 517 citing papers, 5.2% of this breakdownNetherlands: 313 citing papers, 3.2% of this breakdownSpain: 299 citing papers, 3% of this breakdownAustralia: 272 citing papers, 2.7% of this breakdownSwitzerland: 268 citing papers, 2.7% of this breakdownCanada: 259 citing papers, 2.6% of this breakdownJapan: 239 citing papers, 2.4% of this breakdown
0%23.9%Other 23.5%

Fields

  • Medicine72.7%
  • Biochemistry, Genetics and Molecular Biology20%
  • Immunology and Microbiology3.2%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Computer Science0.8%
  • Materials Science0.4%
  • Other2%

Topics

  • Chronic Myeloid Leukemia Treatments12.5%
  • Acute Myeloid Leukemia Research9.4%
  • Chronic Lymphocytic Leukemia Research7.1%
  • Eosinophilic Disorders and Syndromes5.2%
  • Acute Lymphoblastic Leukemia research4.6%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment2.9%
  • Other58.3%

Coauthors

All papers

Open in search
  1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J. L. Steegmann, Anna Turkina, Andrey Zaritskey, R. Hehlmann - Leukemia 2020 cited by 1,510

  2. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 946

  3. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  4. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

    Authors: , , , , , , , , , , , , , , , , , , , , - Leukemia 2021 cited by 351

  5. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 1,885

  6. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2003 cited by 3,565

  7. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

    Authors: , , , , , , , , , , , , , , , , - Leukemia 2016 cited by 850

  8. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 1,679

  9. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John M. Goldman, Rüdiger Hehlmann - Blood 2013 cited by 1,989

  10. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tamar Tadmor, Xavier Troussard, Cecilia Arana Yi, Giuseppe Saglio, Gail J. Roboz, Kemal Balic, Nathan Standifer, Peng He, Shannon Marshall, Wyndham H. Wilson, Ira Pastan, Nai-Shun Yao, Francis J. Giles - Leukemia 2018 cited by 247

  11. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

    Authors: , , , , , , , , , , , , , , , , , , , - Leukemia 2003 cited by 1,528

  12. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

    Authors: , , , , , , , , , , , , , , , , , , , - Leukemia 2017 cited by 287

  13. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Attilio Rovelli, Clara Pecoraro, Alessandro Busca, Francesca Carraro, Franca Fagioli, Susanna Gallo, Daniele Caravelli, Marco De Gobbi, Giuseppe Saglio, Claudia Castellino, Nicola Mordini, Gianluca Gaïdano, Luca Nassi, R Raimondi, Michele Vespignani, Anna Maria Scattolin, Irene Sara Panizzolo, Simone Cesaro, Anna Candoni, Francesca Patriarca, Andrea Bacigalupo, Anna Maria Raiola, Elio Castagnola, Edoardo Lanino, Marta Stanzani, Giuseppe Bandini, Erika Massaccesi, Arcangelo Prete, Simona Bassi, Daniele Vallisa, Cecilia Caramatti, Franco Aversa, Eliana Zuffa, Stefano Guidi, Alberto Bosi, Veronica Tintori, Anna Paola Iori, Saveria Capria, Laura Cudillo, William Arcese, Teresa Dentamaro, Paolo de Fabritiis, Barbara Anaclerico, Anna Chierichini, Monica Piedimonte, Antonella Ferrari, Francesco Marchesi, Andrea Mengarelli, Elisabetta Cerchiara, Maria Cristina Tirindelli, Javid Gaziev, Alessandro Severino, Ignazio Majolino, Patrizia Chiusolo, Simona Sica, Alice Bertaina, Barbarella Lucarelli, Maria Speranza Massei, Alessandra Carotti, Katia Perruccio, Maurizio Caniglia, Stella Santarone, Paolo Di Bartolomeo, Serena Mazzotta, Piero Galieni, Attilio Olivieri, Gennaro De Rosa, Antonio M. Risitano, Mario Delia, Giorgina Specchia and 12 more - Bone Marrow Transplantation 2014 cited by 188

  14. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis

    Authors: , , , , , , - Blood Advances 2020 cited by 132

  15. Chronic myeloid leukemia stem cells

    Authors: , , , , , , , - Leukemia 2019 cited by 175

  16. IKZF1 (Ikaros) Deletions in BCR-ABL1 –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 322

  17. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

    Authors: , , , , , , , , , , , , , , , , , - Leukemia 2021 cited by 86

  18. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 1,298

  19. Molecular Pathways: BCR-ABL

    Authors: , - Clinical Cancer Research 2011 cited by 267

  20. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

    Authors: , , , , , , , , , , , , , , , , , , - Blood 2010 cited by 379

  21. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

    Authors: , , , , , , , , , , , , , - Blood 2011 cited by 579

  22. Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

    Authors: , , , , , , , , , , - American Journal of Hematology 2016 cited by 181

  23. Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 434

  24. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , - Leukemia 2015 cited by 342